All Oncology News

The addition of the anti-TIGIT immunotherapy tiragolumab to atezolizumab plus carboplatin/etoposide failed to significantly improve progression-free survival over atezolizumab/chemotherapy alone when used in the frontline treatment of patients with extensive-stage small cell lung cancer, missing the co-primary end point of the phase 3 SKYSCRAPER-02 trial.

Daniel J. DeAngelo, MD, PhD, discusses how the addition of uproleselan to various chemotherapy backbones is being investigated in ongoing clinical trials, plus the encouraging safety data tied to the lowered mucositis levels.

The FDA has granted priority review to a new drug application seeking the approval of futibatinib in the treatment of patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR2 gene rearrangements, including gene fusions.

Next-generation spatial genomics technology paves the way for accelerating the discovery of new cancer drug targets

Disease progression and acquired resistance to approved EGFR tyrosine kinase inhibitors have resulted in a treatment void in the third- and later-line settings for patients with non–small cell lung cancer.

Encouraging response rates to a dual-targeted regimen in patients with recurrent or refractory malignant brain tumors with BRAF V600E mutations were reported in 2021, representing a new potential targeted therapy strategy against glioblastoma.

Sara M. Tolaney, MD, MPH, reviews practice-changing data sets throughout breast cancer and provides perspective on potential treatment approaches in the absence of definitive results.

Corey S. Cutler, MD, MPH, FRCPC, notes the clinical benefit observed with itolizumab in EQUATE and the observations that informed the design of the phase 3 EQUATOR trial.

Jill Gilbert, MD, discusses pandemic fatigue, loss of connection, and frustration at the collapse of the social contract.

The FDA has granted an orphan drug designation to Veyonda, a novel proprietary formulation of idronoxil, for use as a potential therapeutic option in patients with soft tissue sarcoma.

The European Medicines Agency has validated its type II variation application for nivolumab in combination with chemotherapy for use in the neoadjuvant treatment of patients with unresectable stage IB to IIIA non–small cell lung cancer.

A biologics license application has been submitted to the FDA for the use of mirvetuximab soravtansine monotherapy in patients with platinum-resistant ovarian cancer and high folate receptor–alpha expression who have received 1 to 3 prior systemic treatments.

UCSF’s Division of Hematology-Oncology is welcoming Krishna Komanduri, MD, as division chief of Hematology-Oncology at UCSF Health.

Suresh S. Ramalingam, MD, FACP, FASCO, discusses current applications for frontline immunotherapy and targeted therapy for non–small cell lung cancer and the current management of small cell lung cancer.

Data presented at the ASH Annual Meeting and Exposition underscored the growing focus on improving screening, advancing methods of detection, and improving our understanding of the genomic, genetic, and epigenetic factors that govern progression and therapeutic resistance in multiple myeloma.

The addition of itolizumab to standard-of-care corticosteroids vs placebo will be evaluated in patients with acute graft-versus-host disease, as part of the phase 3 EQUATOR trial.

In acute myeloid leukemia, investigators are exploring novel agents engineered to target adhesion factors, which can mobilize persistent leukemic stem cells from the bone marrow niche.

A pediatric patient with severe transplant-associated thrombotic microangiopathy responded to treatment with narsoplimab after experiencing disease progression on eculizumab.

Florida Cancer Specialists and Research Institute welcomed Ken Sturtz, MBA, MHA to its executive leadership team as Chief Information Officer.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of pembrolizumab for use in combination with chemotherapy with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer who have a PD-L1 combined positive score of 1 or higher.

Fixed-duration systemic therapies have gained some traction in hematologic malignancies, where advances in drug development and sequencing strategies have afforded investigators the opportunity to conduct trials.

R. Lor Randall, MD, discusses takeaways from the American Academy of Orthopaedic Surgeons 2022 Annual Meeting.

Data from a retrospective observational study revealed that White patients with hematologic malignancies in the United States had significantly higher uptake of telemedicine vs Black patients, reflecting disparities that require further exploration.

The Ministry of Health, Labour, and Welfare has accepted a supplemental new drug application for lisocabtagene maraleucel for the second-line treatment of patients with relapsed or refractory large B-cell lymphoma.

The FDA has extended the review period for the supplemental biologics license application for luspatercept-aamt as a treatment for anemia in adults with non–transfusion-dependent β-thalassemia.

The FDA has discouraged the pursuit of a marketing authorization of the PI3K inhibitor zandelisib in patients with follicular lymphoma or marginal zone lymphoma, citing the need for randomized trial data.

The European Commission has expanded the current indication for avapritinib to include use as a single agent in adult patients with aggressive systemic mastocytosis, systemic mastocytosis with an associated hematologic neoplasm, or mast cell leukemia, following at least 1 systemic treatment.

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended pembrolizumab for the treatment of adult patients with a variety of microsatellite instability-high or mismatch repair deficient tumors.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion in favor of the approval of polatuzumab vedotin for use in combination with rituximab plus cyclophosphamide, doxorubicin, and prednisone in patients with previously untreated diffuse large B-cell lymphoma.

The European Medicines Agency’s Committee for Medical Products for Human Use has recommended the approval of ruxolitinib for the treatment of patients with acute or chronic graft-vs-host disease who are aged 12 years or older and who have inadequate response to corticosteroids or other systemic therapies.